MedPath
HSA Approval

RELESTAL PEDIATRIC SYRUP 10 mg/5 ml

SIN12259P

RELESTAL PEDIATRIC SYRUP 10 mg/5 ml

RELESTAL PEDIATRIC SYRUP 10 mg/5 ml

April 25, 2003

FAR EAST DRUG COMPANY (PRIVATE) LIMITED

FAR EAST DRUG COMPANY (PRIVATE) LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFAR EAST DRUG COMPANY (PRIVATE) LIMITED
Licence HolderFAR EAST DRUG COMPANY (PRIVATE) LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

A03AA07

dicycloverine

Manufacturer Information

FAR EAST DRUG COMPANY (PRIVATE) LIMITED

UNITED LABORATORIES INC

Active Ingredients

DICYCLOVERINE HCl

10 mg/5 ml

Dicyclomine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

RELESTAL PEDIATRIC SYRUP 10 mg/5 ml - HSA Approval | MedPath